Antiretroviral News and Research RSS Feed - Antiretroviral News and Research

FDA approves Mylan's ANDA for Fenofibrate Tablets

FDA approves Mylan's ANDA for Fenofibrate Tablets

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has shipped Fenofibrate Tablets, 48 mg and 145 mg. [More]
Hidden HIV replication may be occurring within the body's tissue, researchers report

Hidden HIV replication may be occurring within the body's tissue, researchers report

Scientists have long believed that measuring the amount of HIV in a person's blood is an indicator of whether the virus is actively reproducing. [More]
FDA approves sNDA for SUSTIVA for treatment of HIV-1 infected pediatric patients

FDA approves sNDA for SUSTIVA for treatment of HIV-1 infected pediatric patients

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved a supplemental new drug application for SUSTIVA (efavirenz), including dosing recommendations for HIV-1 infected pediatric patients three months to three years old and weighing at least 3.5 kg. [More]
Synthetic anti-inflammatory substances related to marijuana may help fight HIV infection

Synthetic anti-inflammatory substances related to marijuana may help fight HIV infection

HIV, the virus that causes AIDS, is notorious for hiding within certain types of cells, where it reproduces at a slowed rate and eventually gives rise to chronic inflammation, despite drug therapy. [More]

May issue of WHO Bulletin available online

The May issue of the WHO Bulletin features an editorial examining policy coherence for improved medical innovation and access, a public health news roundup, several research papers on maternal and child health, and a review of 12-month antiretroviral therapy outcomes in low- and middle-income countries, among other articles (May 2013). [More]
Chart presents timeline of HIV prevention options

Chart presents timeline of HIV prevention options

The Center for Global Health Policy's "Science Speaks" blog examines a chart, titled "HIV Prevention Options Timeline," which "was part of AVAC Director Mitchell Warren's presentation at a Jhpiego-sponsored" event on Thursday, titled "The Present and the Future of HIV Prevention." [More]
Highly active ART does not appear to impair heart function, study suggests

Highly active ART does not appear to impair heart function, study suggests

Long-term use of highly active antiretroviral therapies does not appear to be associated with impaired heart function in children and adolescents in a study that sought to determine the cardiac effects of prolonged exposure to HAART on children infected with the human immunodeficiency virus, according to a report published Online First by JAMA Pediatrics, a JAMA Network publication. [More]
Women with HIV who breastfeed exclusively longer than 4 months have lower risk of transmitting virus to infants, study shows

Women with HIV who breastfeed exclusively longer than 4 months have lower risk of transmitting virus to infants, study shows

"The amount of HIV in an infected mother's breast milk spikes when weaning begins, according to a study published [Wednesday] in Science Translational Medicine," Nature reports. [More]
Zambia, Zimbabwe address TB/HIV co-infection

Zambia, Zimbabwe address TB/HIV co-infection

The Center for Global Health Policy's "Science Speaks" blog outlines efforts to fight TB/HIV co-infection in Zambia and Zimbabwe. [More]
Research findings could lead to novel approaches for eliminating reservoirs of HIV-1

Research findings could lead to novel approaches for eliminating reservoirs of HIV-1

Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered how the protein that blocks HIV-1 from multiplying in white blood cells is regulated. [More]

Regional meeting to scale up collaborative TB/HIV activities begins in Maputo

"The regional meeting to scale up collaborative TB/HIV activities in Africa kicked off in Maputo last week with presentations scheduled for 14 African country representatives to share progress and challenges in confronting TB/HIV co-infection in the most highly impacted region of the world," the Center for Global Health Policy's "Science Speaks" blog reports. [More]
Antiretroviral therapy does not affect resting energy expenditure in HIV-infected women

Antiretroviral therapy does not affect resting energy expenditure in HIV-infected women

Studies have shown that about 10 percent of men infected with human immunodeficiency virus have an elevated resting energy expenditure. [More]

Study shows mathematical models can help assess effectiveness of HIV intervention combinations

South Africa is home to the largest HIV epidemic in the world with a total of 5.6 million people living with HIV. Large-scale clinical trials evaluating combination methods of prevention and treatment are often prohibitively expensive and take years to complete. [More]

South Africa announces rollout of new single-dose ARV therapy

"South Africa's Health Minister Aaron Motsoaledi announced on Monday the launch of a new single-dose combination antiretroviral drug that will cost just 89 rand a month ($10) per patient, potentially revolutionizing AIDS treatment in the country," Salon reports (McDonough, 4/9). [More]
Abstracts on Bristol-Myers Squibb's research in liver disease accepted for presentation

Abstracts on Bristol-Myers Squibb's research in liver disease accepted for presentation

Bristol-Myers Squibb Company announced today that 14 abstracts on the Company's research in liver disease have been accepted for presentation at The International Liver CongressTM 2013, the 48th annual meeting of the European Association for the Study of the Liver, in Amsterdam, April 24 - 28. [More]

FDA approves Mylan's ANDA for generic version of Zovirax Ointment

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Acyclovir Ointment USP, 5%. [More]
Reformulated version of anti-HIV gel safe for HIV-negative men and women

Reformulated version of anti-HIV gel safe for HIV-negative men and women

A reformulated version of an anti-HIV gel developed for vaginal use was found safe and acceptable by HIV-negative men and women who used it rectally, according to a Phase I clinical trial published today in PLOS ONE. [More]

Different metrics should be used in different settings to measure ARV program success

Studies show "the profound impact of antiretroviral-therapy coverage at a population level" -- how wider coverage can increase life expectancy and reduce the risk of HIV infection. [More]

Organizations highlight World TB Day

World TB Day is commemorated each year on March 24, recognizing the discovery of the tuberculosis bacilli by Robert Koch in 1882. [More]

Mylan gets final approval from FDA for generic Xopenex Inhalation Solution

Mylan Inc. today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg/3 mL (0.042%), (Concentrate). [More]